Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?

Annals of the American Thoracic Society

Volumn 11, Issue 4, 2014, Pages 562-570

  Ooi, Chee Y ^a,c   Dupuis, Annie ^d,e   Gonska, Tanja ^a,b   Ellis, Lynda ^b   Ni, Andy ^d   Jarvi, Keith ^f   Martin, Sheelagh ^b   Ray, Peter ^a,g   Steele, Leslie ^g,h   Kortan, Paul ^h   Dorfman, Ruslan ^a   Solomon, Melinda ^a,g   Zielenski, Julian ^a   Corey, Mary ^d,e   Tullis, Elizabeth ^h,i   Durie, Peter ^a,b  

^a Research Institute   (United States)

^b Division of Gastroenterology   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Child Health Evaluative Sciences ^*  (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cystic fibrosis; Diagnosis; Genotyping; Nasal potential difference; Sweat test

Indexed keywords

AMILORIDE; CHLORIDE; ION CHANNEL; ISOPRENALINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PERFUSION; PHENOTYPE; PROSPECTIVE STUDY; SWEAT; SWEAT TEST; ADOLESCENT; AZOOSPERMIA; CASE CONTROL STUDY; CHEMISTRY; CHILD; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; NOSE MUCOSA; PANCREATITIS; PARANASAL SINUS DISEASES; PRINCIPAL COMPONENT ANALYSIS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AZOOSPERMIA; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; PANCREATITIS; PARANASAL SINUS DISEASES; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SWEAT; YOUNG ADULT;

EID: 84903576864     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201311-412OC     Document Type: Article

References (41)

1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. (Pubitemid 19231813)
2. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653-658. (Pubitemid 28402089)
3. Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J, Berthiaume Y, Corey M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011;140:153-161.
4. Bishop MD, Freedman SD, Zielenski J, Ahmed N, Dupuis A, Martin S, Ellis L, Shea J, Hopper I, Corey M, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005;118:372-381. (Pubitemid 43091209)
5. Ooi CY, Durie PR. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros 2012; 11:355-362.
6. Gonska T, Choi P, Stephenson A, Ellis L, Martin S, Solomon M, Dupuis A, Dorfman R, Zielenski J, Ooi CY, et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest 2012;142:996-1004.
7. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gilè LS, Luisetti M, Pignatti PF. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 1998;103: 718-722. (Pubitemid 29020770)
8. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010;182: 614-626.
9. Jarvi K, Zielenski J, Wilschanski M, Durie P, Buckspan M, Tullis E, Markiewicz D, Tsui LC. Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. Lancet 1995;345:1578.
10. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006;174:787-794. (Pubitemid 44511660)
11. Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Gonska T, Dorfman R, Kortan P, Solomon M, Tullis E, et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? Thorax 2012;67:618-624.
12. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al.; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14. (Pubitemid 351970581)
13. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011;10:S86-S102.
14. Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Gonska T, Dorfman R, Kortan P, Solomon M, Tullis E, et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis (CF) among patients with single-organ manifestations of CF? Thorax 2014;69:254-260.
15. CFTR2 Team. Clinical and functional translation of CFTR. Baltimore, MD: John Hopkins University; 2011. Available from: http://www.cftr2.com
16. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013;45:1160-1167.
17. Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001;17:1208-1215. (Pubitemid 32717480)
18. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, et al. CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004;127: 1085-1095. (Pubitemid 39345878)
19. Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E, Conrad D, Shamsuddin AK, Durie P, Gonska T. b-Adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012;186:732-739.
20. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson PF, Parekh RV, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 2012; 44:562-569.
21. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011;43: 539-546.
22. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
23. Zielenski J, Aznarez I, Onay T, Tzounzouris J, Markiewicz D, Tsui LC. CFTR mutation detection by multiplex heteroduplex (mHET) analysis on MDE gel. Methods Mol Med 2002;70:3-19.
24. Férec C, Casals T, Chuzhanova N, Macek M Jr, Bienvenu T, Holubova A, King C, McDevitt T, Castellani C, Farrell PM, et al. Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms. Eur J Hum Genet 2006;14:567-576.
25. Audrézet MP, Chen JM, Raguénès O, Chuzhanova N, Giteau K, Le Maréchal C, Quéré I, Cooper DN, Férec C. Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms. Hum Mutat 2004;23:343-357. (Pubitemid 38461516)
26. Pearson K. On lines and planes of closest fit to systems of points in space. Philos Mag 1901;6:559-572.
27. Hotelling H. Analysis of a complex of statistical variables into principal components. J Educ Psychol 1933;24:417-441.
28. Sermet-Gaudelus I, Girodon E, Sands D, Stremmler N, Vavrova V, Deneuville E, Reix P, Bui S, Huet F, Lebourgeois M, et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med 2010;182:929-936.
29. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-850.
30. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (DF508). N Engl J Med 1990;323:1517-1522.
31. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 2012;7:e48370.
32. Konieczna L, Skokowski J, Olȩdzka I, Macur K, Belka M, Ba̧czek T, Struck W, Markuszewski M. The osteopontin tissue level as a breast cancer biomarker in females after mastectomy measured by the capillary gel electrophoresis technique. Comb Chem High Throughput Screen 2013;16:331-338.
33. Jian W, Sun X, Luo S. Computer-aided diagnosis of breast microcalcifications based on dual-tree complex wavelet transform. Biomed Eng Online 2012;11:96.
34. Lloyd GR, Orr LE, Christie-Brown J, McCarthy K, Rose S, Thomas M, Stone N. Discrimination between benign, primary and secondary malignancies in lymph nodes from the head and neck utilising Raman spectroscopy and multivariate analysis. Analyst (Lond) 2013;138: 3900-3908.
35. Sidhu GS, Asgarian N, Greiner R, Brown MR. Kernel principal component analysis for dimensionality reduction in fMRI-based diagnosis of ADHD. Front Syst Neurosci 2012;6:74.
36. Ratuapli SK, Bharucha AE, Noelting J, Harvey DM, Zinsmeister AR. Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology 2013;144:314-322, e2.
37. Han TS, Stimson RH, Rees DA, Krone N, Willis DS, Conway GS, Arlt W, Walker BR, Ross RJ; United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2013;78:197-203.
38. Gottfries CG, Hager O, Gottfries J, Zachrisson O. Immunotherapy of fibromyalgia and chronic fatigue syndrome by a staphylococcus toxoid vaccine. Bull IACFS/ME 2009-2010;17:168-183.
39. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, et al.; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-1083.
40. Collaco JM, McGready J, Green DM, Naughton KM, Watson CP, Shields T, Bell SC, Wainwright CE, Cutting GR; ACFBAL Study Group. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One 2011;6:e27784.
41. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006;173:1139-1144. (Pubitemid 43726895)